Do persistent spike proteins cause long COVID or other post-vaccine symptoms?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Current evidence shows SARS‑CoV‑2 spike protein can persist in blood and tissues for months to years after infection and has plausible biological effects that could drive symptoms, but the literature is mixed on whether persistence is a cause of long COVID or post‑vaccine syndromes rather than a marker of other processes; some studies find associations and mechanistic effects in animals, while others find no clear link to clinical severity, and leading researchers now call for targeted clinical trials to test causality and treatments [1] [2] [3] [4].
1. What the data actually show about persistence
Multiple human and animal studies have detected spike protein or spike fragments long after acute infection—in plasma and in organs including skull, meninges and brain—sometimes for a year or more, and sensitive assays report spike or S1 in a substantial fraction (up to ~60–65%) of people with post‑acute symptoms in some cohorts [1] [5] [6] [7]. These same teams and others also document that spike accumulates at brain borders in post‑mortem samples and that vaccination reduces but does not always eliminate tissue accumulation after infection in animal models [2] [6].
2. Mechanistic plausibility: why spike could matter
Experimental work shows that spike protein alone can induce inflammation, neuroinflammatory changes, synaptic dysfunction and exacerbate brain injury in rodents, and proteomic and CSF changes consistent with neurodegeneration have been reported in affected humans—findings that supply a biologically plausible pathway from persistent spike to symptoms such as cognitive impairment and fatigue [2] [8] [9]. These mechanistic datasets underpin proposals that lingering spike could drive chronic inflammation or autoimmunity in some patients [10] [9].
3. Association vs causation in human studies
Human observational work is inconsistent: several studies find persistent spike more often in people with long COVID and hypothesize it may be a biomarker or driver, while other controlled cohorts report persistent serum spike in both recovered controls and patients without a statistically significant correlation to symptom severity or clinical markers—meaning that detection alone does not prove spike causes symptoms [5] [11] [3] [12]. Scientific American quoted study authors who explicitly consider spike may simply mark residual infected tissue rather than be the proximate cause of symptoms [12].
4. Post‑vaccine symptoms and 'post‑vaccination syndrome' — an open question
Investigators studying post‑vaccination syndromes (PVS) find higher spike levels in some individuals with persistent symptoms after vaccination, even without detectable infection, and they are explicitly testing whether removing spike (for example with monoclonal antibodies) might alter symptoms; however, these programs are early and do not yet establish causation, and sequence differences between vaccinal spike mRNA and wild‑type viral spike are invoked as a tool to distinguish sources in investigations [4] [1]. Surveillance and reviews emphasize alternative drivers—autoimmunity, tissue damage, and viral reactivation (e.g., EBV)—so spike persistence is one hypothesis among several under active study [4].
5. What this means for patients and research priorities
The conservative interpretation supported by current reporting is that persistent spike is a credible and testable contributor to some cases of long COVID or PVS because of detection in affected tissues and experimental effects in animals, but the evidence is not yet uniform or definitive enough to say it is the primary cause across patients; randomized interventional trials that target spike clearance and careful stratification (who has tissue or blood spike versus who does not) are the logical next step advocated by researchers to move from association to proof [4] [9] [3]. Given conflicting results across cohorts and the multiple plausible mechanisms for post‑infectious and post‑vaccination symptoms, research must remain agnostic and pursue mechanistic trials rather than premature clinical claims [3] [12].